Future Oncology is an analytical newsletter for executives, researchers, and market analysts in the pharmaceutical, biotechnology, financial, hospital and other health care industries. It provides comprehensive, up-to-date analysis of scientific, technological, clinical and commercial developments in oncology.
Topics Covered in Future Oncology:
Worldwide (North America, Europe, Japan, etc.) mortality and incidence estimates by gender, cancer subtype and stage; estimates of populations carrying certain markers and under treatment by type of therapy.
Mechanism in Malignancy
Etiology, pathogenesis and markers by type of cancer; exploitation of mechanisms of malignancy (apoptosis, angiogenesis, cell cycle regulation, multi-drug resistance, etc.) in screening, diagnosis, disease monitoring, prognosis and drug development, including databases of agents in development.
Technological advances such as in vivo and ex vivo gene therapy using a variety of vectors and delivery approaches, monoclonal antibodies in diagnosis and therapy, radiopharmaceuticals, photodynamic therapy, immunotherapy/vaccines, hematopoietic support, and many more.
Drugs in Development, Markets and Developers
Profile of major oncology drug classes (taxanes, topoisomerase I inhibitors, platinum-based drugs, cell cycle regulators, etc.), estimated worldwide markets for commercialized drugs, descriptions of oncology-related operations of various commercial entities, including their affiliations.
Coverage of meetings in the cancer and related fields such as the International Congress on Anti-Cancer Chemotherapy (ICACC); International Conference on Monoclonal Antibody Immunoconjugates for Cancer; Annual Meeting of the American Association for Cancer Research (AACR); Digestive Disease Week; Annual Session of the American Society of Clinical Oncology (ASCO); Annual Meeting of the Society of Nuclear Medicine; International Congress of Chemotherapy; Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); and many more.